ArticleFrontiers in neurology2024
Global burden of multiple sclerosis and its attributable risk factors, 1990-2019.
Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Crossroads of Neuroinflammation and Biomarkers in Multiple Sclerosis: A Systematic Review.Cells · 2026Pooled it
- Metabolomics in Multiple Sclerosis: Advances, Challenges, and Clinical Perspectives-A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study.JAMA neurology · 2026Trial
- Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction in Patients With Multiple Sclerosis: A Pilot Trial.Neurourology and urodynamics · 2025Trial
- Lifetime exposure to shift work and risk of multiple sclerosis: retrospective and prospective cohort studies in UK Biobank.Occupational and environmental medicine · 2026Article
- Serum 25-hydroxyvitamin D and neurological disability in multiple sclerosis: a cross-sectional study in a Libyan multicenter cohort.Acta neurologica Belgica · 2026Article
- Reliable Uncertainty Under Class Imbalance and Distribution Shift: Class-Conditional Conformal Prediction of Multiple Sclerosis.medRxiv : the preprint server for health sciences · 2026Article
- Assessing the Early Economic Feasibility of a Curative Gene Therapy for Multiple Sclerosis Using a Risk-Adjusted Valuation Framework.Healthcare (Basel, Switzerland) · 2026Article
- Psychological Burden in Relapsing-Remitting Multiple Sclerosis: Sociodemographic and Clinical Determinants of Persistent Anxiety and Depression over a Six-Month Follow-Up.Nursing reports (Pavia, Italy) · 2026Article
- Predicting Quality of Life in Relapsing-Remitting Multiple Sclerosis: Clinical Burden Meets Emotional Balance in Early Disease.Neurology international · 2025Article
- Sex-Related Differences in Lifestyle Factors Affecting Multiple Sclerosis Susceptibility and Disease Progression.Brain sciences · 2025Review
- The Utility of Intravoxel Incoherent Motion Metrics in Assessing Disability in Relapsing-Remitting Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2025Article
- Analysis of the onset of lower urinary tract symptoms in multiple scleroris patients.World journal of urology · 2025Observational
- Beyond weight loss: exploring the neurological ramifications of altered gut microbiota post-bariatric surgery.Journal of translational medicine · 2025Review
- Cortico-hippocampal molecular characterization in rat model of multiple sclerosis: Neuroprotective mechanisms ofMultiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS) is a progressively debilitating disorder that has seen a notable rise in prevalence in recent years. This study examines the burden of MS from 1990 to 2019, providing a detailed analysis by age, sex, and sociodemographic index (SDI) across 204 countries and territories. Methods: Data on the prevalence, death and disability-adjusted life years (DALYs) attributable to MS were obtained from the publically available Global Burden of Disease 2019 project. The estimates are reported as numbers, percentages, and age-standardized rates per 100,000, accompanied by 95% uncertainty intervals. Results: In 2019, MS accounted for 1.8 million prevalent cases, 22.4 thousand deaths and 1.2 million DALYs worldwide. There were significant declines in the global age-standardized prevalence, mortality and DALY rates of MS over the period 1990-2019. In 2019, females exhibited a higher global point prevalence and a greater total number of prevalent MS cases than males across all age groups. At the regional level, a non-linear relationship was observed between the age-standardized DALY rate of MS and SDI. Conclusion: Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. Integrating MS and its associated risk factors into healthcare planning is vital, especially in areas with high levels of socioeconomic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.